Mdfi - MyoD family inhibitor

Predicted to enable DNA-binding transcription factor binding activity and identical protein binding activity. Predicted to be involved in several processes, including dorsal/ventral axis specification; negative regulation of transcription by RNA polymerase II; and regulation of signal transduction. Predicted to act upstream of or within embryonic skeletal system morphogenesis and trophoblast giant cell differentiation. Predicted to be active in nucleus. Orthologous to human MDFI (MyoD family inhibitor). [provided by Alliance of Genome Resources, Apr 2022]